

Table 3. Commonly Used Abbreviations

| Abbreviation | Definition and Notes |
|--------------|--|
| ACA | Patient Protection and Affordable Care Act |
| AFP | alpha-fetoprotein |
| ALT | alanine aminotransferase |
| AMP | average manufacturer price |
| Anti-HCV | HCV antibody |
| APRI | AST-to-platelet ratio index |
| AST | aspartate aminotransferase |
| AUC | area under the curve |
| AWP | average wholesale price ^a |
| BOC | boceprevir |
| CBC | complete blood count |
| CDC | Centers for Disease Control and Prevention |
| CEA | cost-effectiveness analysis |
| CTP | Child-Turcotte-Pugh (see below) |
| CYP | cytochrome P450 |
| DAA | direct-acting antiviral |
| eGFR | estimated glomerular filtration rate |
| ESRD | end-stage renal disease |
| FDA | US Food and Drug Administration |
| GFR | glomerular filtration rate |
| HBsAg | hepatitis B virus surface antigen |
| HBV | hepatitis B virus |
| HCC | hepatocellular carcinoma |
| HCV | hepatitis C virus Hepatitis C virus and HCV refer to the virus. Hepatitis C and HCV infection or HCV disease refer to the disease entity. |

| Abbreviation | Definition and Notes |
|--------------------------|--|
| ICER | incremental cost-effectiveness ratio |
| IDU | injection drug use or user |
| INR | international normalized ratio |
| MELD | model for end-stage liver disease |
| MSM | men who have sex with men |
| NASH | nonalcoholic steatohepatitis |
| NAT | nucleic acid testing |
| NIH | National Institutes of Health |
| NS3 | HCV nonstructural protein 3 |
| NS5A | HCV nonstructural protein 5A |
| OATP | organic anion-transporting polypeptide |
| PBM | pharmacy benefit manager |
| PCR | polymerase chain reaction |
| P-gp | P-glycoprotein |
| PreP | preexposure prophylaxis |
| PWID | people who inject drugs |
| QALY | quality-adjusted life-year |
| RAS | resistance-associated substitution |
| RBC | red blood cell(s) |
| RBV | ribavirin |
| RGT | response-guided therapy |
| sAg | surface antigen |
| SMV | simeprevir |
| SOF | sofosbuvir |
| SVR12 (or 24 or 48, etc) | sustained virologic response at 12 weeks (or at 24 weeks, or at 48 weeks, etc) |
| TSH | thyroid-stimulating hormone |
| TVR | telaprevir |

| Abbreviation | Definition and Notes |
|--|---|
| ULN | upper limit of normal |
| USPSTF | US Preventive Services Task Force |
| WAC | wholesale acquisition cost ^b |
| ^a "List price" for wholesale pharmacies to purchase drugs ^b Typically, approximately 17% off of AWP | |

| Child-Turcotte-Pugh (CTP) Classification of the Severity of Cirrhosis | | | |
|---|---------|--|------------------------------|
| | CLASS A | CLASS B | CLASS C |
| Total Points | 5-6 | 7-9 | 10-15 |
| Factor | 1 Point | 2 Points | 3 Points |
| Total bilirubin (µmol/L) | <34 | 34-50 | >50 |
| Serum albumin (g/L) | >35 | 28-35 | <28 |
| Prothrombin time / international normalized ratio | <1.7 | 1.71-2.3 | >2.3 |
| Ascites | None | Mild | Moderate to Severe |
| Hepatic encephalopathy | None | Grade I-II (or suppressed with medication) | Grade III-IV (or refractory) |

Last update: September 21, 2017